Renowned photographer Rankin and CSL Behring team up to launch ‘Portraits of Progress’, an exhibition chronicling the past, present and future of living with hemophilia

by Rankin the first in-person U.S. exhibit in three years features portraits and personal stories highlighting remarkable advances in understanding and treating hemophilia and hopes for the future

KING OF PRUSSIA, Pa., June 9, 2022 /PRNewswire/ — CSL Behring, world leader in biotherapeutics and renowned portrait photographer Rankin have partnered to launch “Portraits of Progress,” a multimedia campaign featuring the stories and experiences of people living with hemophilia from the mid-20th century to today. This exhibition, the first of its kind, introduces visitors to the remarkable pace of progress in the treatment of hemophilia, from the identification of hemophilia A and B in the 1940s, to the therapeutic advances available today. today and continuing research focused on gene therapies for the bleeding disorder.

Check out the interactive multi-channel press release here:

“I’ve worked with the hemophilia community for 35 years, and it’s been amazing to see the advances that have been made in both treatment and education,” said a woman named Sue, a hematology nurse coordinator at the retirement, whose portrait and history are presented in the exhibition. “Thanks to medical and therapeutic advances, people with hemophilia who receive proper treatment live longer than ever before and have the freedom to do more. We never know what the future holds, but I think looking at all the research and everything on the horizon, there will only be positive things for our bleeding disorders community. »

“Portraits of Progress” is an immersive multimedia exhibit designed to educate about living with hemophilia by documenting the progress in our understanding of the disease and the community’s hopes for the future. Featuring portraits of people with hemophilia, caregivers and medical professionals photographed by Rankinalong with personal stories, archival footage and a timeline of key scientific discoveries, viewers are drawn from life in the 1950s and 1960s when life expectancies were less than 20 years, through the evolution of transformative recombinant therapies in the 1990s and 2000s, for the prospect of a single-dose treatment under investigation that could offer even more possibilities for patients in the future.

Opening on June 11 in New York City and on tour in the United States and Europe later in the year, “Portraits of Progress” will be by Rankin first live exhibition in the United States in three years.

“As a photographer, I’ve turned to campaigns that can make a difference,” Rankin said. “Hemophilia is something I thought I understood, but I realized there was so much to learn. Listening to these exceptional stories and learning more about the extraordinary journey of this community has been truly an education and a privilege. I hope this exhibit will lead to greater awareness and understanding of hemophilia and the amazing people within this tight-knit community. »

The exhibition is located at 89 Crosby Street, Soho, New York City and run to June 19 of 10 a.m. to 6 p.m. Daily. The exhibition can also be viewed virtually at

“Driven by our promise to support people living with rare and serious diseases, CSL Behring has a long history of innovation and collaboration with the bleeding disorders community, whether through cutting-edge treatments or our programs that provide education, support and connection,” said Bob Lojewski, Senior Vice President and General Manager of North American Business Operations, CSL Behring. “We are constantly impressed by this incredible group of people, and we hope ‘Portraits of Progress’ will shine a light on this vibrant and engaged community and inspire those who live with hemophilia every day.”

About hemophilia
Hemophilia is a rare disease in which the blood does not clot normally because it does not contain enough blood-clotting proteins, called clotting factors. The two most common types of hemophilia are A and B. Hemophilia A is the most common type of hemophilia and is caused by a lack of blood clotting factor VIII, while hemophilia B is caused by a lack of factor IX (FIX). The more severe the disease, the less a person is able to form blood clots, which makes them more vulnerable to bleeding.

People with the disease are particularly vulnerable to bleeding into joints, muscles and internal organs, leading to pain, swelling and joint damage. Current treatment includes lifelong prophylactic clotting factor infusions to temporarily replace or supplement low blood clotting factor levels.

About gene therapy
In general, gene therapies are an innovative approach to treating medical conditions by introducing a functional or working gene into the body or by turning off or changing the gene causing the condition.

Current treatments for hemophilia work to temporarily replace or supplement low blood clotting factor levels, but gene therapy has the potential to restore near-normal blood clotting ability.

Clinical trials of gene therapy for hemophilia are still ongoing and none are currently approved by the Food and Drug Administration (FDA). Experimental gene therapies aim to allow patients to create their own factor through a single infusion, potentially providing long-lasting protection against bleeding for years. Gene therapy can potentially provide long-term benefits of sustained factor activity levels from a single treatment administration, potentially reducing or even eliminating the need for regular long-term prophylaxis.

About Rankin
Rankin is a British photographer, editor and director. He is best known for his work at the forefront of culture and the forefront of future trends, producing campaigns that break the rules.

As a photographer, by Rankin portfolio ranges from portrait to documentary. He has photographed several high profile musicians, actors, models and cultural icons.

As an editor, Rankin co-founded the founding magazine Dazed & Confused, and has since published over 40 books and founded the print and digital platform Hunger.

by Rankin work has been published everywhere, from his own exhibitions at Elle, Vogue, Esquire, GQ, Rolling Stone and Wonderland, and exhibited in galleries around the world, including MoMA, New Yorkand the Victoria & Albert Museum, London.

About CSL Behring
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on meeting patient needs using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the therapeutic areas of immunology, hematology, cardiovascular and metabolic diseases, breathing and transplants. We use three strategic science platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continuous innovation and continually refine the ways in which products can address unmet medical needs and help patients to lead full lives.

CSL Behring operates one of the largest plasma collection networks in the world, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people worldwide and provides its lifesaving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita and follow us on Behring.

Media Contact
Etanjalie Ayala
Mobile: +1 610 297 1069
E-mail: [email protected]


Comments are closed.